The combination of PDGF-B, HRAS, and sh-p53 vectors produces a more robust and efficient model of high-grade glioma than any other combination tested in the present study, which can lead to better preclinical testing for spinal cord glioma treatments. Here, PDGFB is linked to spinal cord glioma.